Fig. 1: Upregulation of FOXP4 correlates with poor prognosis for OV patients.

A The expressions of FOXP4 in 33 types of human cancer in data from TCGA dataset through GEPIA2 online website (https://gepia2.cancer-pku.cn). The gene expression profile across all tumor samples and paired normal tissues is shown as a dot plot. Ret dot represents cancer sample and green dot represents normal sample. B Boxplot analysis of differences in FOXP4 expression levels in ovarian tissues from the GEPIA2 website. T, Tumor tissues; N, Normal tissues; *P-value was set at 0.01. C The mRNA expression of FOXP4 from different OV TNM stages in an independent OV patient cohort (GSE140082). *p < 0.05, **p < 0.01, ***p < 0.001. D Using UALCAN network platform (http://ualcan.path.uab.edu/) analysis FOXP4 mRNA expression level and patient age. This is visually represented by a box plot. *p < 0.05, **p < 0.01, ***p < 0.001. E The protein level of FOXP4 from normal ovary tissue and OV tissues from Clinical Proteomic Tumor Analysis Consortium (CPTAC). FOXP4 was selectively highly expressed in Wnt pathway-altered OV tissues. F Single-cell sequencing showed that FOXP4 is highly expressed in OV malignant tumor cells. G The representative IHC staining of FOXP4 protein in OV tissue (Ovarian serous cystadenocarcinoma) and normal tissue (ovary) from the Human Protein Atlas Project (http://www.proteinatlas.org/). ***p < 0.001. H, I The prognostic values of FOXP4 in OV patients. The survival curves comparing OV patients with high (red) and low (black) FOXP4 expression levels were plotted using the online Kaplan–Meier Plotter (https://kmplot.com/). OS, overall survival rate (H); PFS, progression free survival rate (I).